These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37742907)

  • 1. "Buprenorphine, It Works so Differently": Adults with Sickle Cell Disease Describe Transitioning to Buprenorphine for Treatment of Chronic Pain.
    Prince E; Loeser P; Early M; Carroll CP; Lanzkron S; Pecker LH
    J Pain; 2024 Mar; 25(3):632-641. PubMed ID: 37742907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine for Chronic Pain in a Pediatric Patient With Sickle-Cell Disease.
    Irwin M; Gunther W; Keefer P; Saul D; Singh SA; Wright J; Smith MA
    J Pain Symptom Manage; 2021 Nov; 62(5):1086-1091. PubMed ID: 33864846
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic: A Qualitative Study.
    Sinha CB; Bakshi N; Ross D; Krishnamurti L
    JAMA Netw Open; 2019 May; 2(5):e194410. PubMed ID: 31125105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative Analysis of Patient Perspectives of Buprenorphine After Transitioning From Long-Term, Full-Agonist Opioid Therapy Among Veterans With Chronic Pain.
    Edmond SN; Wesolowicz DM; Snow JL; Currie S; Jankelovits A; Chhabra MS; Becker WC
    J Pain; 2024 Jan; 25(1):132-141. PubMed ID: 37549775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid treatment for acute and chronic pain in patients with sickle cell disease.
    Carroll CP
    Neurosci Lett; 2020 Jan; 714():134534. PubMed ID: 31593753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization.
    David MS; Jones J; Lauriello A; Nnake I; Plazas Montana M; Lasko K; Buri-Nagua C; Olagbaju Y; Williams E; Sears M; Salzberg B; Lanzkron SM; Carroll CP
    Am J Hematol; 2022 Nov; 97(11):1435-1442. PubMed ID: 36053825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report.
    Leyde S; Suen L; Pratt L; DeFries T
    J Gen Intern Med; 2022 Apr; 37(5):1281-1285. PubMed ID: 34993878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease.
    Buchheit BM; Joslin T; Turner HN; Wong TE
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28766. PubMed ID: 33111401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine in the Treatment of Chronic Pain.
    Rudolf GD
    Phys Med Rehabil Clin N Am; 2020 May; 31(2):195-204. PubMed ID: 32279723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically.
    Suzuki J; Matthews ML; Brick D; Nguyen MT; Wasan AD; Jamison RN; Ellner AL; Tishler LW; Weiss RD
    J Opioid Manag; 2014; 10(3):159-68. PubMed ID: 24944066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of severe chronic pain with methadone in pediatric patients with sickle cell disease.
    LeBlanc Z; Vance C; Payne J; Zhang J; Hilliard L; Lebensburger JD; Howard TH
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27084. PubMed ID: 29749702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommending buprenorphine for pain management.
    Ehrlich AT; Darcq E
    Pain Manag; 2019 Jan; 9(1):13-16. PubMed ID: 30507294
    [No Abstract]   [Full Text] [Related]  

  • 14. Pain in sickle cell disease: current and potential translational therapies.
    Sagi V; Mittal A; Tran H; Gupta K
    Transl Res; 2021 Aug; 234():141-158. PubMed ID: 33711512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization.
    Berland DW; Malinoff HL; Weiner MA; Przybylski R
    Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.
    Webster L; Gudin J; Raffa RB; Kuchera J; Rauck R; Fudin J; Adler J; Mallick-Searle T
    Pain Med; 2020 Apr; 21(4):714-723. PubMed ID: 31917418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Complex Association of Daily Opioid Dose with Visits for Pain in Sickle Cell Disease: Tolerance or Treatment-Refractory Pain?
    Prince EJ; Pecker LH; Lanzkron S; Carroll CP
    Pain Med; 2023 Jun; 24(6):703-712. PubMed ID: 36458906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Pain Does Not Impact Baseline Circulating Cytokine Levels in Adults with Sickle Cell Disease.
    Karafin MS; Simpson P; Field JJ
    Acta Haematol; 2021; 144(1):111-116. PubMed ID: 32403100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
    Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.